A Peer-Reviewed Publication Written by Leslie S.T. Fang, MD, PhD
Pradaxa® (dabigatran) and Xarelto® (rivaroxaban) are two new oral anticoagulants that are striving to replace Coumadin® in the management of patients with non-valvular atrial fibrillation. The drugs have rapid onset of action, are taken in a fixed dose, do not require PT/INR monitoring and there are no dietary restrictions for the patients on these agents. This has led to a rapid adoption by physicians. It is therefore important for the dental professional to understand the mechanism of action of these drugs in order to intelligently manage these patients when they need dental intervention. The pros and cons of interruption of therapy are discussed as they apply to patients needing simple and complex dentistry. Medical consultation is mandatory prior to interruption of anticoagulant therapy.
At the conclusion of this educational activity the participant will be able to:
- Describe Pradaxa® (dabigatran) and Xarelto® (rivaroxaban) and why are they increasingly prescribed
- Discuss how these newer oral anticoagulants differ from Coumadin®
- Manage simple and complex dental procedures in a patient on newer oral anticoagulants
- Safely utilize drugs commonly prescribed by dentists for patients on newer oral anticoagulants
- Describe the drugs commonly prescribed by dentists which should be avoided in patients on newer oral anticoagulants
To view this course in its entirety, please click here.
Past DE Issues